Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
企業コードBFRI
会社名Biofrontera Inc
上場日Oct 14, 2021
最高経営責任者「CEO」Luebbert (Hermann)
従業員数92
証券種類Ordinary Share
決算期末Oct 14
本社所在地120 Presidential Way,
都市WOBURN
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号01801
電話番号17812451325
ウェブサイトhttps://www.biofrontera-us.com/
企業コードBFRI
上場日Oct 14, 2021
最高経営責任者「CEO」Luebbert (Hermann)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし